75659-16-4

Upstream product

• 75624-30-5 O-benzyl-α-N-t-BOC-D-threonine 
• 622-33-3 N-benzyloxyamine 
• 75624-31-6 tert-butyl ((2S,3R)-1-((benzyloxy)amino)-3-hydroxy-1-oxobutan-2-yl)carbamate 
• 2592-18-9 Boc-Thr-OH 
• 75624-30-5 O-benzyl-α-N-t-BOC-D,L-allo-threonine hydroxamate 
• 2592-18-9 N-t-BOC-D,L-allo-threonine 
• 1972-28-7 diethylazodicarboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 80542-48-9 (3S-trans)-3-(t-butyloxycarbonylamino)-1-hydroxy-4-methyl-2-azetidinone 
• 286939-11-5 (2S,3S)-3-((benzyloxy)amino)-2-((tert-butoxycarbonyl)amino)butanoic acid 
• 286939-12-6 (2S,3S)-2-[(tert-butoxycarbonyl)amino]-3-[(N-benzyloxy-N-methyl)amino]butanoic acid 
• 87791-60-4 4-methyl-3-<(tert-butoxycarbonyl)amino>-1-dibenzylphosphoryl-2-azetidinone 
• 82933-50-4 (2S,3S)-1-(benzyloxy)-2-methyl-4-oxoazetidin-3-ylammonium tosylate salt 

Relevant academic research and scientific papers

Synthetic Sansanmycin Analogues as Potent Mycobacterium tuberculosis Translocase i Inhibitors

Herein, we report the design and synthesis of inhibitors of Mycobacterium tuberculosis (Mtb) phospho-MurNAc-pentapeptide translocase I (MurX), the first membrane-associated step of peptidoglycan synthesis, leveraging the privileged structure of the sansanmycin family of uridylpeptide natural products. A number of analogues bearing hydrophobic amide modifications to the pseudo-peptidic end of the natural product scaffold were generated that exhibited nanomolar inhibitory activity against Mtb MurX and potent activity against Mtb in vitro. We show that a lead analogue bearing an appended neopentylamide moiety possesses rapid antimycobacterial effects with a profile similar to the frontline tuberculosis drug isoniazid. This molecule was also capable of inhibiting Mtb growth in macrophages where mycobacteria reside in vivo and reduced mycobacterial burden in an in vivo zebrafish model of tuberculosis.

Progress in the development of β-lactams as N-Acylethanolamine Acid Amidase (NAAA) inhibitors: Synthesis and SAR study of new, potent N-O-substituted derivatives

The anti-inflammatory effects resulting from raising the levels of palmitoylethanolamide (PEA), an endogenous bioactive lipid, led to envisage N-Acylethanolamine Acid Amidase (NAAA), the cysteine hydrolase mainly responsible for PEA degradation, as an att

2-oxoazetidin-1-yloxy acetic acids and analogs

Antibiotic activity is exhibited by β-lactams having an STR1 substituent (and analogs thereof) in the 1-position and an acylamino substituent in the 3-position.

Crystalline anhydrous aztreonam

The crystalline anhydrous form of [3S-[3α(Z), 4β]]-3-[[(2-amino-4-thiazolyl) [(1-carboxy-1-methylethoxy)imino]acetyl]amino]-4-methyl-2-oxo-1-azetidinesulfonic acid is prepared.

2-OXO-1-AZETIDINESULFONIC ACID SALTS

Antibacterial activity is exhibited by beta-lactams having a sulfonic acid salt substituent in the 1-position and an amino or acylamino substituent in the 3-position.

3-acylamino-2-oxo-1-azetidinyl esters of phosphonic acids, phosphoric acid and phosphoric acid esters

Antimicrobial activity is exhibited by β-lactams having a STR1 substituent in the 1-position and an acylamino substituent in the 3-position, or a pharmaceutically acceptable salt thereof; wherein Y is oxygen or sulfur and R5 is hydroxyl, alkyl, substituted alkyl, phenyl, substituted phenyl, alkoxy, alkylthio, (substituted alkyl)oxy, (substituted alkyl)thio, phenyloxy, phenylthio, (substituted phenyl)oxy or (substituted phenyl)thio.

2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines

Antibacterial activity is exhibited by β-lactams having a STR1 substituent in the 1-position and an acylamino substituent in the 3-position wherein Z is oxygen or sulfur, and R is alkyl, alkenyl, alkynyl, substituted alkyl, phenyl, substituted phenyl, a 5